New Evidence Shows Long COVID Neurological Effects Subside by 1 Year

A NATIONWIDE cohort study demonstrates that post-acute neuromuscular conditions and long-term neurocognitive effects attenuate within one year. Using 14.4 billion insurance claims representing 244.7 million U.S. patients, investigators analyzed whether persistent neurological and physical deficits stem directly from viral pathophysiology or unmeasured testing bias.

Refining Long COVID Neurological Effects

Initial observational research suggested long-term neurocognitive sequelae persist indefinitely. However, unrestricted control cohorts frequently matched tested individuals against untested peers, capturing health-seeking behaviors rather than true clinical causality. By enrolling patients exclusively at their initial PCR test and matching test-positive cases to test-negative controls, the study revealed 83.5% fewer attributable conditions between 30 and 119 days. Long COVID neurological effects such as myopathy emerged with an elevated relative risk of 3.1 during the early post-acute phase, confirming genuine acute neuromuscular vulnerability. Despite high relative risk, the low baseline prevalence translated to modest absolute excess risk in monthly claims.

Neuromuscular Trajectories Over 2 Years

Between 120 and 359 days postinfection, elevated risk persisted for myopathy alongside systemic issues, but absolute risk differences fell close to baseline. Related chronic complaints like post-infectious fatigue remained statistically detectable solely due to high population prevalence. By days 360 to 719, attributable risk ratios for all evaluated conditions dropped below 1.1 with zero outcomes meeting significance after Bonferroni correction. Negative control outcomes, including adult cerebral palsy, demonstrated that prior designs suffered from massive positive confounding. While persistent symptoms beyond twelve months remain clinically impactful, their direct etiologic attribution to viral infection remains unconfirmed.

For physicians managing patients with persistent neuromuscular concerns, these revised data underscore the necessity of differentiating true post-acute viral sequelae from underlying conditions or non-COVID health factors that initially prompted clinical evaluation. Because relative risk attenuates significantly toward population baseline by one year, unexplained late-onset neurological signs warrant comprehensive diagnostic workups for alternative primary pathologies. Ultimately, advancing targeted clinical care will depend on validating specific biological markers and uncovering the precise pathophysiological mechanisms underlying true post-viral neuromuscular injury.

Reference

Nilforoshan H et al. Revised estimates of types and duration of long COVID symptoms based on claims records from 245 million US patients. PNAS. 2026;123(44):e2604414123.